Are all glitazones the same? - PubMed (original) (raw)
Review
. 2002 Mar-Apr:18 Suppl 2:S1-4.
Affiliations
- PMID: 11921431
Free article
Review
Are all glitazones the same?
Luc Van Gaal et al. Diabetes Metab Res Rev. 2002 Mar-Apr.
Free article
Abstract
This supplement focuses on the benefits of targeting insulin resistance through therapy with a new class of oral antidiabetic agents, the thiazolidinediones (TZDs) or 'glitazones'. There are important differences between the three TZD class members that warrant discussion to enable physicians to make rational and informed therapeutic choices between the agents. Overall the TZDs appear to be similar in their effects on blood glucose, as all class members have demonstrated effective glycaemic control, both as monotherapy and in combination with sulphonylureas, metformin or exogenous insulin. The safety profiles of the three agents are more diverse, with what appear to be 'TZD class effects', (probably mediated via activation of peroxisome proliferator-activated receptor gamma [PPAR gamma]) and 'TZD-specific effects', which are unique to each agent and may be a consequence of differing chemical structures. While rosiglitazone and pioglitazone share some class effects with troglitazone, they have several characteristics that define them as unique agents. By tackling the control of type 2 diabetes through direct effects on insulin resistance, the TZDs represent an important new therapeutic tool for healthcare professionals.
Similar articles
- Promising new approaches.
Reasner CA 2nd. Reasner CA 2nd. Diabetes Obes Metab. 1999 May;1 Suppl 1:S41-8. Diabetes Obes Metab. 1999. PMID: 11220287 Review. - Pioglitazone and rosiglitazone for diabetes.
[No authors listed] [No authors listed] Drug Ther Bull. 2001 Sep;39(9):65-8. Drug Ther Bull. 2001. PMID: 11586802 Review. - Repaglinide in combination therapy.
Moses R. Moses R. Diabetes Nutr Metab. 2002 Dec;15(6 Suppl):33-8. Diabetes Nutr Metab. 2002. PMID: 12702006 Review. - Differentiating members of the thiazolidinedione class: a focus on safety.
Lebovitz HE. Lebovitz HE. Diabetes Metab Res Rev. 2002 Mar-Apr;18 Suppl 2:S23-9. doi: 10.1002/dmrr.252. Diabetes Metab Res Rev. 2002. PMID: 11921435 Review. - Differentiating members of the thiazolidinedione class: a focus on efficacy.
Goldstein BJ. Goldstein BJ. Diabetes Metab Res Rev. 2002 Mar-Apr;18 Suppl 2:S16-22. doi: 10.1002/dmrr.251. Diabetes Metab Res Rev. 2002. PMID: 11921434 Review.
Cited by
- Glycaemic control is still central in the hierarchy of priorities in type 2 diabetes management.
Khunti K, Zaccardi F, Amod A, Aroda VR, Aschner P, Colagiuri S, Mohan V, Chan JCN. Khunti K, et al. Diabetologia. 2025 Jan;68(1):17-28. doi: 10.1007/s00125-024-06254-w. Epub 2024 Aug 19. Diabetologia. 2025. PMID: 39155282 Free PMC article. Review. - Molecular dynamic simulations reveal the mechanism of binding between xanthine inhibitors and DPP-4.
Gu Y, Wang W, Zhu X, Dong K. Gu Y, et al. J Mol Model. 2014 Feb;20(2):2075. doi: 10.1007/s00894-014-2075-1. Epub 2014 Jan 31. J Mol Model. 2014. PMID: 24481594 - Combined thiazolidinedione-insulin therapy: should we be concerned about safety?
Scheen AJ. Scheen AJ. Drug Saf. 2004;27(12):841-56. doi: 10.2165/00002018-200427120-00002. Drug Saf. 2004. PMID: 15366973 Review. - Thiazolidinediones decrease vascular endothelial growth factor (VEGF) production by human luteinized granulosa cells in vitro.
Shah DK, Menon KM, Cabrera LM, Vahratian A, Kavoussi SK, Lebovic DI. Shah DK, et al. Fertil Steril. 2010 Apr;93(6):2042-7. doi: 10.1016/j.fertnstert.2009.02.059. Epub 2009 Apr 1. Fertil Steril. 2010. PMID: 19342033 Free PMC article. - Pioglitazone and sulfonylureas: effectively treating type 2 diabetes.
Hanefeld M. Hanefeld M. Int J Clin Pract Suppl. 2007 Jun;61(153):20-7. doi: 10.1111/j.1742-1241.2007.01361.x. Int J Clin Pract Suppl. 2007. PMID: 17594390 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical